- No file added yet -
NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease.
journal contribution
posted on 2016-02-29, 12:53 authored by Brian Lawlor, Sean Kennelly, Sarah O'Dwyer, Fiona Cregg, Cathal Dominic Walsh, Robert Cohen, Rose Anne Kenny, Robert Howard, Caroline Murphy, Jessica Adams, Leslie Daly, Ricardo Segurado, Siobhan Gaynor, Fiona Crawford, Michael Mullan, Ugo Lucca, Rita Banzi, Florence Pasquier, Laetitia Breuilh, Matthias W. Riepe, Janos Kalman, Anders Wallin, Anne Borjesson-Hanson, William Molloy, Magda Tsolaki, Marcel Olde RikkertThis study is a European multicentre,
randomised, double-blind, placebo-controlled trial
investigating the efficacy and safety of nilvadipine as a
disease course modifying treatment for mild-tomoderate
Alzheimer’s disease (AD) in a phase III study
that will run for a period of 82 weeks with a treatment
period of 78 weeks
Funding
Study on Aerodynamic Characteristics Control of Slender Body Using Active Flow Control Technique
Japan Society for the Promotion of Science
Find out more...STTR Phase I: Fully Implantable, Ultra-Flexible Wireless Electrode Array for Brain Activity Mapping
Directorate for Technology, Innovation and Partnerships
Find out more...History
Publication
BMJ Open;4: e006364Publisher
BMJ Publshing GroupNote
peer-reviewedOther Funding information
ERCLanguage
EnglishExternal identifier
Usage metrics
Categories
No categories selectedLicence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC